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Summary Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the
plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR)
assayto demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the
blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium
chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich
for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39%) patients, all confirmed bysequencing, but was not
detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location,
principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients
were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable
by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma- or serum-based nucleic acid amplification assays
may provide a valuable method of monitoring and potentially detecting colorectal cancer.
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Colorectal cancer is a common and often fatal disease for which
methods ofearly detection andmonitoring are needed. While early
detection and prompt medical intervention can be curative, many
patients present with regional or widespread metastasis, reflecting
in part the limitations ofcurrent screening methods. Mutations of
the K-ras oncogene are detected in approximately 40% ofpatients
with colorectal cancer, with these mutations occurring in the later
stages ofadenoma development and persisting during clonal trans-
formation (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al,
1988). As most K-ras mutations are restricted to a few adjacent
nucleotides of codons 12 and 13, nucleic acid amplification
assays, such as the polymerase chain reaction (PCR), can be used
to detect small numbers ofthese mutant ras oncogenes. The diag-
nostic potential of this tumour-specific approach was demon-
strated by Sidransky et al (1992), who used PCR to detect ras
mutations in stool from patients with benign or malignant
neoplasms ofthe colon. PCR has been used to detect K-ras muta-
tions in the sputum ofpatients with lung cancer (Yakubovskaya et
al, 1995) and in both pancreatic secretions and blood from patients
with pancreatic cancer (Tada et al, 1993). Similarly, Hardingham
et al (1995) demonstrated that circulating K-ras mutant colorectal
cancer cells can be detected in blood using PCR. Nucleic acid
amplification assays have also been used to detect circulating
cancer cells in the blood of patients with various other malignan-
cies, including lymphoma (Gribben et al, 1994), leukaemia
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(Pichert et al, 1994), prostate cancer (Moreno et al, 1992;
Ghossein et al, 1995), malignant melanoma (Hoon et al, 1995;
Smith et al, 1991), breast cancer (Datta et al, 1994) and hepato-
cellular cancer (Komeda et al, 1995).
Most PCR-based studies evaluating the blood of cancer patients
have focused on the cellular fraction of blood as they attempt to
detect circulating cancer cells. An alternative and perhaps more
efficacious method to detect mutant K-ras DNA involves analysis
of the plasma or serum fraction of blood. Extracellular DNA
normally circulates in the plasma component of blood in small
amounts (Foumie et al, 1986), and significant increases in the
amount ofcirculating DNA are noted in patients with cancer (Leon
et al, 1977), possibly correlating with tumourviability (Stroun etal,
1987, 1989). Shapiro et al (1983) demonstrated that patients with
gastrointestinal cancers have significant elevations of serum DNA
compared with patients with benign gastrointestinal diseases.
Recently, it has been shown that mutated ras oncogene DNA canbe
detected in plasma or serum by PCR. Sorenson et al (1994) found
mutated K-ras DNA in the plasma ofthree patients with metastatic
pancreatic cancer, with the sequences ofmutated genes detected in
plasma matching those of the primary tumour. Vasioukhin et al
(1994) detected N-ras mutations in the plasma of patients with
acute myelogenous leukaemia and myelodysplastic syndrome.
Vasyukhin et al (1994) have similarly detected mutant K-ras DNA
in the plasma from 6 of 15 patients with colorectal cancer.
In this larger study, we combine efficient DNA extraction
methods with a sensitive PCR assay to detect mutant K-ras DNA
in plasma and serum. We confirm that mutant K-ras DNA is
readily detectable in the blood of patients with colorectal cancer,
but not in the blood of normal volunteers. These findings suggest
that analysis ofblood plasma or serum for mutant oncogene DNA
might provide a valuable method of monitoring and potentially
diagnosing patients with colorectal cancer.
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MATERIALS AND METHODS
Specimens
Five to ten millilitres of peripheral blood were collected from 31
patients with metastatic (30 patients) or unresected primary (one
patient) colorectal cancer and from 28 normal volunteers. For
plasma preparation, EDTA-coated or citrate Vacutainer tubes were
used to avoid the potential inhibitory effects ofheparin on the ampli-
fication assay (Beutler et al, 1990). In other cases, clotted blood
specimens were obtained. Blood was centrifuged at 4°C and 850g
for 10 min, then the plasma (22 patients, 28 normal volunteers) or
serum (nine patients) fraction was removed and stored frozen at
- 70°C. Ofthe patient samples, 15 were collected prospectively and
were stored for 1-6 months before assaying. The remaining 16
samples had been collected in 1988 and had been stored for more
than 6 years before assaying. All normal volunteer samples had been
collected recently and had been frozen for a short time. Paraffin
blocks of tumours were available for 19 patients, including 18
primary tumours and four metastatic lymph node specimens.
Plasma and serum DNA extraction
DNA was extracted from plasma or serum by one of two methods.
In extraction method one (25 patients, 13 normal volunteers),
adapted from Fedorov et al (1986), 200 pl of serum or plasma was
mixed with an equal volume of 3.45 M sodium chloride, then
boiled for 4 min, slowly cooled to room temperature over 30 min
and refrigerated at 4°C for 20 h. The samples were then
centrifuged at 3000 g for 30 min. One hundred and eighty
microlitres of supernatant was removed and loaded in two separate
aliquots onto a Sephadex G50 column (Quick Spin, Boehringer
Mannheim, Indianapolis, IN, USA) equilibrated with TE (10 mM
Tris pH 7.0, 1 mm EDTA) that had been prepared previously
according to the manufacturer's instructions. The column was
eluted at 1100 g for 4 min per aliquot. The resultant eluate was
reduced in volume to approximately 70 pl by vacuum desiccation.
One half ofthis amount was used in the PCR assay.
In extraction method two (six patients, 15 normal volunteers),
plasma or serum DNA was co-precipitated with gelatin by a
method modified from that of Fournie et al (1986). A stock 5%
(w/v) gelatin solution was prepared by mixing 1 g of gelatin
(G8-500, Fisher, Pittsburgh, PA, USA) with 20 pl ofsterile, double-
distilled water, autoclaving for 30 min and filtering through a 0.2-
gm filter. The resultant solution was sequentially frozen in a dry
ice/ethanol bath and thawed at room temperature for a total of five
cycles. A working 0.3% gelatin solution was prepared by heating
the stock solution to 60°C and mixing 600 p1 of5% gelatin with 25
pl of 1 M Tris-HCl (pH 8.0) and 9.4 pl of sterile, double-distilled
water. One hundred and sixty microlitres of plasma or serum was
mixed with 12.8 pl of 0.5 M EDTA and 467 pl of sterile, double-
distilled water, then emulsified for 3 min with 320,l of phenol.
The solution was centrifuged at 14 000 g for 10 min, and 570 pl of
the aqueous layer was removed to a clean tube. DNA was precipi-
tated by addition of 142 p1 ofthe 0.3% (w/v) gelatin working solu-
tion and 500 pl ofcold absolute ethanol, followed by incubation at
- 20°C for a minimum of2 h. The samples were microfuged at 4°C
for 15 min, washed once with cold 70% ethanol and dried in a 60°C
heat block for 10 min. DNA was resuspended by the addition of70
p1 of sterile, double-distilled water preheated to 60°C. One-half of
each sample was used in the PCR assay.
PCR assay
Mutant K-ras oncogene DNA was isolatedusing a non-radioactive
PCR assay adapted from Kahn et al (1991). PCR was performed as
follows: a reaction mixture containing 35 pl of the DNA solution
extracted from plasma or serum, 50 mm potassium chloride,
10 mM Tris pH 9.0, 0.1% Triton X-100, 1.5 mm magnesium chlo-
ride, 200,M of each dATP, dGTP, dCTP and dTTP, 0.5 pmol
oligonucleotide K-ras-L (5'-ACTGAATATAAACTTGTGGTA-
GTTGGACCT-3'), 0.75 pmol oligonucleotide K-ras-R (5'-
TCAAAGAATGGTCCTGGACC-3') and 1 unit ofTaq DNApoly-
merase (Promega, Madison, WI, USA) in a volume of 50 pl was
prepared. The stated ratio of primers was found empirically to
provide the cleanest results (not shown). The oligonucleotide
K-ras-L is immediately upstream of codon 12 and is modified at
the 28th base (G > C) to create an artificial restriction enzyme site
(BstNI). The oligonucleotide K-ras-R is modified at the 17th
nucleotide (C > G) to create an artificial BstNI site to serve as an
internal control for completion ofdigestion. This approach differs
from the original (Kahn et al, 1991), in which an unmodified
K-ras-R primer was used in the first round and the modified
primer only in the second round ofamplification. Our approach is
simpler and yields equivalent sensitivity (data not shown).
The reaction mixture was overlaid with mineral oil and cycled
15 or 20 times at 94°C for 48 s, 56°C for 90 s and 72°C for 155 s
in a PHC-2 thermocycler (Techne, Princeton, NJ, USA). Ten
microlitres of the PCR mixture were then removed to a new tube,
adjusted to be equivalent to 1 x BstNI reaction buffer, and 10 units
ofBstNI restriction enzyme (Stratagene, La Jolla, CA, USA) were
added and then incubated at 60°C for 90 min. A second aliquot of
10 units of BstNI was added and the reaction was continued for
90 min more. Ten microlitres of the digested PCR mixture was
then removed to a new tube and a new reaction mixture was set up
forthe second amplification stage using identical constituents as in
the first amplification, except that 7.7 pmol of oligonucleotide
K-ras-L and 11.5 pmol ofoligonucleotide K-ras-R were used. The
same cycling conditions were used for 33 or 35 cycles. A second
BstNI restriction digestion was performed using 25 gl of the
second-step PCRproduct and 17 units ofenzyme in a final volume
of35 pl. Digestions were performed for 60 min, and then a second
aliquot of 10 units ofenzyme was added and digested for an addi-
tional 60 min. The final digestion product was electrophoresed
through a 3% agarose gel.
All amplification assays included a mutated K-ras-positive
control consisting ofthe coron carcinoma cell line GEO (codon 12
K-ras mutation GGT > GCT), a wild-type K-ras (mutant negative)
control consisting ofDNA from normal placenta tissue and a nega-
tive control lacking DNA. In addition, reactions were run in
parallel without BstNI digestion to ensure amplification had
occurred. Routine precautions to prevent contamination were used
in all amplification-based work (Kwok and Higuchi, 1989). The
risk of contamination yielding falsely positive results was further
minimized by repeating PCR assays on all patient plasma or serum
samples two or three times on different days.
Paraffin tissue extraction
DNA was harvested from tissue in available paraffin blocks by
cutting 2-4 paraffin sections at a thickness of 15 microns using
ethanol-cleaned microtome blades. The tissue was transferred to
microfuge tubes and extracted twice with 300 p1 of xylene to
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remove paraffin, then washed twice with 300 gl of 70% ethanol
and finally with 300 pl of 10 mm Tris, 1 mm EDTA. The tissue
was then resuspended in 300-500 g1 of proteinase K buffer
(200 mm Tris HCl pH 8.0, 100 mm EDTA, 1% sodium dodecyl
sulphate, 500 jg ml-' proteinase K) and digested at 48°C for
24 to 48 h, with 100 ,ug of proteinase K added after 12 h of
digestion. Serial extractions with equal volumes of phenol-
chloroform and chloroform-isoamyl alcohol were performed,
followed by precipitation with two volumes of ethanol and
300 mm sodium acetate, pH 5.6. The pellet was washed in 70%
ethanol, dried and resuspended at 55°C for 10 min in 200 pl of
10 mm Tris, 1 mm EDTA. Two hundred microlitres of the DNA
solution was loaded on a Sephadex G50 spin column in two
aliquots and centrifuged according to the manufacturer's instruc-
tions. This was then reduced in volume to approximately 70,l
by vacuum desiccation.
PCR assays for K-ras mutations were performed essentially as
described, with 35 pul of DNA solution added to the PCR reaction
mixture. The two-stage PCR assay consisted of an initial 15-cycle
amplification, followed by reamplification ofdigested products for
an additional 30 cycles, with the final product being electro-
phoresed through a 3% agarose gel. Positive controls (GEO cell
line) and negative controls (placenta tissue and reagents without
template DNA) were included in all amplification assays. In addi-
tion, equivalent amounts of tumour DNA were run in parallel
without BstNI digestion to ensure that amplification at the locus
had occurred.
Gel electrophoresis
Twenty-five microlitres of the final digestion product were
electrophoresed through a 3% agarose (2:1 NuSieve GTG, FMC
Bioproducts, Rockland, ME, USA; Molecular Biology Grade
Agarose, Promega) gel in 1 x TBE at 75 V DC forapproximately 2
h before staining with ethidium bromide. Photographs of the gels
were taken on an ultraviolet light transilluminator (Foto-prep,
Fotodyne, Hartland, WI, USA). Mutant K-ras DNA was evident
on the gel as a single band of length 142 bp, failure of digestion
was evident as a band at 157 bp and cleaved non-mutated (wild-
type) K-ras DNA was sometimes evident as a band at 113 bp.
Sequence analysis
To confirm results of the plasma and serum specimen assays
mutant DNA bands were excised from the agarose gel, reampli-
fied, cloned into the pGEM-T vector plasmid (Promega) and
sequenced using a commercial kit (Sequenase 2.0, USB,
Cleveland, OH, USA). A minimum of two clones were sequenced
for each PCR product, and all gave consistent results.
Clinical correlations
Clinical variables that might affect plasma or serum K-ras detec-
tion were reviewed retrospectively. Comparisons were made
between detection of mutant K-ras DNA in plasma or serum and
patient sex, primary tumour location (colon vs rectum), principal
metastatic site (liver vs lung) and proximity of chemotherapy or
surgical resection to specimen blood draw. Statistical analysis
was performed using Fisher's exact test for a two by two table
(two-tail).
1 2 3 4 5 6 7 8 9 10
Figure 1 Gel electrophoresis demonstrating detection of mutant K-ras DNA
in plasma from colorectal cancer patients (lanes 4-7). Lane 1, uncut DNA
control; lane 2, GEO cell line positive control; lane 3, 1:10 000 dilution of
positive control; lane 8, placenta (wild-type) negative control; lane 9, DNA-
absent negative control confirming lack of contamination; lane 10, molecular
weight markers (Phi X174 DNA cut with Haelll)
RESULTS
PCR was performed on blood plasma and serum, primary tumours
and lymph node metastases. Serial dilutions indicate the sensitivity
of the PCR assay to be one mutant gene out of 105 normal genes
(data not shown).
Plasma and serum specimens
All 28 plasma and serum specimens from normal volunteers tested
negative for mutant K-ras DNA regardless of extraction method
used. Of31 cancer patient plasma and serum specimens, 12 (39%)
were positive for mutant K-ras DNA, with a distinct band seen on
the gels at the 142 bp length (Figure 1). Positive samples included
8 of the 22 plasma specimens and four of the nine serum speci-
mens. Both extraction methods appeared efficacious, with mutant
K-ras detected in 8 of 25 specimens for which extraction method
one was used and in four of six specimens for which extraction
method two was used. All positive specimens were repeatedly
positive on retesting of the specimen. The remaining 19 patient
plasma and serum specimens repeatedly tested negative. To make
certain that negative results were not due to failed amplifications,
specimens were further tested by omitting the initial BstNI diges-
tion. The expected wild-type K-ras band was formed in all cases
indicating that amplifiable DNA was present in each sample. In all
PCR runs, the positive GEO control tested positive, and the nega-
tive placenta and DNA absent controls tested negative. The one
patient without evidence of metastatic disease whose blood was
drawn before surgical resection of his rectal primary tested nega-
tive for mutant K-ras DNA in his blood. His tumour was unavail-
able for testing.
Tumour specimens
Tissue blocks were available for 19 patients, including 18 patients
for whom the primary tumour specimen was available. One patient
had only a metastatic nodal specimen available. Additional lymph
node blocks were available in three other patients to compare with
primary tumour specimens.
K-ras mutations were detectable in the tumours or nodes of six
(32%) of these patients. Tumours from the remaining 13 patients
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Table 1 Mutation sequences and tissue comparisons for patients with mutant K-ras-positive plasma or serum
Patient Blood specimen Tissue specimen
Type of specimen Mutation sequence Mutant K-ras (+I-)
1 P GAT NA
2 S GCT
3 S GCT +
4 P GAT NA
5 P GAT +
6 S GAT +
7 S GAT
8 P GAT
9 P GAT +
10 P GAT +
11 P GTT,GAT NA
12 P GAT NA
P, plasma; S, serum; NA, tissue not available.
Patient 9
of three patients (Table 1, patients 2, 7 and 8). Only a single block
of tumour was available for testing from each of these patients. In
contrast, of the six patients who demonstrated K-ras mutations in
their cancers, plasma or serum was positive for mutant ras DNA in
five cases, with one patient having a ras-positive tumour and ras-
negative blood. The available metastatic lymph node from that
patient was similarly negative for ras mutation. With this exception,
concordance for ras mutation was noted between primary tumours




Figure 2 Sequencing results from extracellular mutant K-ras DNA. A single
representative clone from each of three patients is shown; two to four mutant
clones were obtained from all patients. The mutant base in codon 12 is
indicated on the left. The wild-type sequence reads (from bottom up)
ACCTGGTGGC, with codon 12 underlined and the base altered by primer
mismatching italicized (see text)
were negative for mutant K-ras. Plasma and serum specimens were
correlated with the available tissue. Of the 19 patients, plasma or
serum was positive for mutant K-ras DNA in eight patients, with
tumours or nodes being mutant ras positive in five ofthese patients.
Ofthe 13 patients with primary tumours negative for mutant K-ras
DNA, plasma or serum was negative for ras mutations in ten. Thus,
K-ras mutations were detectable in the blood but not in the tumours
Sequence analysis
Sequence analysis ofplasma and serum PCR products from the 12
mutant ras-positive blood specimens confirmed that the detected
K-ras DNA was mutated (Figure 2 and Table 1). These mutations
included nine instances of GGT > GAT, two cases of GGT > GCT
and one case ofGGT > GTT plus GAT. Ofnote, three patients had
mutant ras detected in their blood but not in their tumour. Two of
these patients had GGT > GAT mutations, making contamination
by the GEO control cell line, which carries a GCT mutation,
unlikely. The third patient had a GGT > GCT mutation.
Clinical correlations
All patients (18 men, 13 women) had either metastatic colorectal
carcinoma (30 patients) or an unresected but not metastatic
primary rectal cancer (one patient) at the time of their blood draw,
with parenchymal metastasis involving predominantly liver (18
patients), lung (five patients), both liver and lung (five patients) or
omentum/ascites (two patients). Initial primary tumours originated
from the colon in 20 patients and from the rectum in 11 patients.
Mutant K-ras DNA could be detected in patient plasma or serum
regardless ofpatient sex, initial primary tumour location (colon vs
rectum) or principal parenchymal metastatic site (liver vs lung).
Differences in the detection of mutant ras DNA among patients
grouped by these clinical variables were not significant, although
group sizes were small (Table 2).
The proximity of specimen blood draw to chemotherapy and
surgery were further investigated. While recognizing that advanced
colorectal cancer responds poorly to chemotherapy, it is possible
that chemotherapy might increase circulating mutant ras through
cellular necrosis or apoptosis or might decrease circulating mutant
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Table 2 Correlation between clinical variables and detection of mutant K-ras DNA in plasma or serum
Clinical variable No. of patients No. of patients with P-value
mutant K-ras DNA in blood
Sex
Male 18 8 0.48
Female 13 4
Primary tumour
Colon 20 10 0.13
Rectum 11 2
Principal metastatic site
Liver 18 9 1.00
Lung 5 2
Chemotherapy
Within 3 months 13 5 1.00
Naive or free > 6 months 13 6
ras by a reduction in tumour burden. Chemotherapeutic histories
were available for 29 patients. Of these, 13 patients had a history
of having received chemotherapy within 3 months before their
specimen blood draw, with mutant K-ras DNA detected in the
plasma or serum of five of these patients, including three of the
seven patients who had received chemotherapy within the
preceding month. However, 13 other patients had their blood
sample drawn before initiation of chemotherapy, i.e. while still
chemotherapy-naive (nine patients), or after having been
chemotherapy-free for at least 6 months (four patients). Mutant
K-ras DNA was detected in the plasma or serum in six of these
patients (four chemotherapy-naive patients, two chemotherapy-
free patients). Differences regarding circulating mutant ras DNA
in the recent chemotherapy and chemotherapy-naive/-free groups
were not significant (P = 1.00). Similarly, surgery might release
circulating tumour cells or traumatize cells, promoting mutant ras
detection. However, of the 12 patients with K-ras mutations
detected in their blood, only one patient had the blood specimen
drawn within 1 month after surgery, while seven had their blood
specimen drawn more than 1 year after surgery. Conclusions
cannot be extrapolated to the intraoperative and immediate post-
operative periods, as no blood specimens were obtained during
these times. Thus, the above data demonstrate that mutant K-ras
DNA circulates in plasma or serum even without recent surgical
trauma or chemotherapy-induced necrosis or apoptosis.
Blood specimens from 16 patients were collected in 1988 and
stored frozen. Mutations were detected in the plasma or serum in
four ofthese specimens, indicating that mutant K-ras DNA can be
detected in plasma and serum frozen long term. Whether the sensi-
tivity of the assay is diminished when specimens are stored under
these conditions remains uncertain.
DISCUSSION
Mutation of the K-ras oncogene is recognized as an early and
frequent mutational event in the pathogenesis ofcolorectal cancer,
making it a potentially valuable clinical marker. As the location of
ras point mutations is fairly restricted, with most occurring at
codons 12, 13 or 61, they are particularly amenable to detection by
nucleic acid amplification assays (Bos, 1989). In this study we
have combined DNA extraction methods with a non-radioactive
PCR assay to demonstrate that mutant K-ras DNA is readily
detectable in the plasma and serum of patients with advanced
colorectal cancer. The presence of mutant ras DNA in plasma has
similarly been demonstrated by others. Sorenson et al (1994)
combined a dialysis-based DNA extraction procedure with PCR to
detect mutant K-ras DNA in the plasma ofpatients with pancreatic
cancer. Vasioukhin and associates (1994) used PCR to amplify
DNA extracted from plasma through centrifugation on a caesium
sulphate gradient and were able to demonstrate circulating N-ras
mutations in patients with leukaemia and myelodysplastic
syndrome. Vasyukhin et al (1994) similarly extracted DNA from
the plasma of patients with colorectal cancer and were able to
amplify mutant K-ras DNA. While we used different DNA extrac-
tion methods, sensitivity and reproducibility were maintained.
DNA extraction method two in particular has the advantage of
being rapid, with DNA extracted from plasma in as little as 3 h.
Although we did not demonstrate complete concordance
between K-ras mutations in plasma or serum and those in tumours,
it appears that we were able to detect most cases with circulating
mutant K-ras DNA. Our detection ofcirculating mutantras in 39%
ofthe patients is similar to what wouldbe expected based upon the
incidence of K-ras mutations in colorectal cancer. There was a
single case of a primary tumour bearing a K-ras mutation that was
not detectable in blood. Of interest, examination of a metastatic
node from the patient also failed to detect mutant ras, raising the
possibility that the patient's remaining metastatic tumours either
lost or never carried the mutation. Three patients had K-ras muta-
tions detectable in their blood but not in their primary tumours.
Results for these three patients probably indicate circulating extra-
cellular mutant K-ras DNA, with several factors making contami-
nation unlikely: all normal control specimens tested negative;
placenta and DNA-absent controls tested negative; results were
consistently reproducible upon retesting of the specimens; and
sequence analysis confirmed specific mutations, of which two of
the three cases differed from the positive control. Other investiga-
tors have reported ras mutations in the metastasis but not in the
corresponding primary tumour, or in the primary tumour but not in
the metastasis (Oudejans et al, 1991). Sampling ofblood plasma or
serum might prove a particularly efficacious means of detecting
mutant DNA should such tumour heterogeneity be present,
because it effectively screens the entire tumour burden.
It is not known whether mutant K-ras DNA in plasma and serum
represents extracellular DNA released from viable tumour, DNA
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released from necrotic or apoptotic cells or DNA released from the
lysis of fragile circulating cancer cells. It is well documented that
circulating cancer cells can be detected in blood (Hardingham et
al, 1995). However, it has been observed both by us and by others
(Vasioukhin et al, 1994; Vasyukhin et al, 1994) that mutant ras can
be detected in plasma even when not detected in the cellular frac-
tion of blood, suggesting that circulating cancer cells may not be
involved. Cellular necrosis and apoptosis are common processes in
cancer. Conceivably, such processes could yield detectable
amounts of extracellular DNA, either as free DNA or as
membrane-bound apoptotic bodies. An alternative possibility is
that detectable extracellular DNA is being shed from viable
tumour (Leon et al 1977). An active release of DNA that appears
to be independent of cell death but under regulatory control has
been demonstrated in lymphocytes (Rogers et al, 1972; Anker et
al, 1975). Furthermore, DNA has been demonstrated on the cell
surface of malignant cell lines (Aggarwal et al, 1975; Juckett and
Rosenberg, 1982). It is commonly assumed that shed extracellular
DNA would be susceptible to digestion by plasma DNAases.
However, Leon et al (1981) found inhibitors of DNAase in the
plasma of cancer patients, which might lead to accumulation of
circulating DNA. Others have suggested that DNA is shed in a
protein or proteolipid complex and is thus resistant to degradation
(Rogers et al, 1974; Stroun et al, 1977, 1987).
Regardless of the origin of this extracellular DNA, the use of
plasma-based nucleic acid amplification assays to detect tumour-
specific extracellular DNA represents a new and potentially valu-
able approach to cancer detection and monitoring. This initial
study was limited primarily topatients with metastatic disease, and
the use of our assay in detecting early disease remains undefined.
In general, the applicability of K-ras assays to cancer detection
and monitoring will be limited by the incidence of K-ras muta-
tions, with over halfofcolorectal cancers reported to be mutant K-
ras negative. However, the concept of selective amplification of
mutant DNA from plasma or serum can be extended to other onco-
genes and tumour-suppressor genes, including p53, which is
frequently mutated in colorectal cancer. Although the mutated
nucleotides in the p53 gene are not as clustered as in the K-ras
oncogene, a panel or multiplex approach using a number of
primers could allow increased detection of cancers. Furthermore,
it has recently been demonstrated that tumour-associated
microsatellite alterations can be detected in the plasma DNA of
small-cell lung cancer patients (Chen et al, 1996) and the serum
DNA of head and neck cancer patients (Nawroz et al, 1996). As
microsatellite alterations are often present in colorectal tumours
(Lothe et al, 1993; Bocker et al, 1996), they should similarly be
detectable in the plasma and serum DNA of colorectal patients.
Plasma and serum-based assays aimed at cancer monitoring might
additionally be improved using a quantitative PCR approach. The
screening, diagnostic and monitoring potential of detecting onco-
genes or other tumour-associated DNA in plasma and serum and
the pathophysiological function and clinical implication of their
presence warrant further investigation.
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